{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:23:58Z","timestamp":1792005838687,"version":"4.4.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1,28]]},"DOI":"10.1097\/qad.0b013e3283333666","type":"journal-article","created":{"date-parts":[[2010,1,19]],"date-time":"2010-01-19T00:43:18Z","timestamp":1263861798000},"page":"353-563","source":"Crossref","is-referenced-by-count":14,"title":["The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters"],"prefix":"10.1097","volume":"24","author":[{"given":"Esteban","family":"Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fehmida","family":"Visnegarwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Grund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avis","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Gibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Shlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraser","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafaa","family":"El-Sadr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00002030-200101260-00013","article-title":"Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV\/AIDS treatment database","volume":"15","author":"Heath","year":"2001","journal-title":"AIDS"},{"key":"R2-6-20210130","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-200107270-00008","article-title":"Clinical assessment of HIV-associated lipodystrophy in an ambulatory population","volume":"15","author":"Lichtenstein","year":"2001","journal-title":"AIDS"},{"key":"R3-6-20210130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1468-1293.2003.00159.x","article-title":"HIV lipodystrophy: prevalence, severity and correlates of risk in Australia","volume":"4","author":"Miller","year":"2003","journal-title":"HIV Med"},{"key":"R4-6-20210130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00126334-200209010-00007","article-title":"Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort study","volume":"31","author":"Bernasconi","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R5-6-20210130","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/00126334-200212010-00006","article-title":"Impact of lipodystrophy on the quality of life of HIV-1-infected patients","volume":"31","author":"Blanch","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R6-6-20210130","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1086\/383573","article-title":"Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1","volume":"38","author":"Blanch","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"R7-6-20210130","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1097\/00126334-200212153-00011","article-title":"Relationship between HAART adherence and adipose tissue alterations","volume":"31","author":"Ammassari","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R8-6-20210130","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1177\/135965350701200713","article-title":"Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy","volume":"12","author":"Guaraldi","year":"2007","journal-title":"Antivir Ther"},{"key":"R9-6-20210130","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/ncpendmet0587","article-title":"Therapy insight: body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy","volume":"3","author":"Falutz","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"R10-6-20210130","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study","volume":"357","author":"Martinez","year":"2001","journal-title":"Lancet"},{"key":"R11-6-20210130","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/QAI.0b013e3181142d26","article-title":"Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides: dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384","volume":"45","author":"Dub\u00e9","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R12-6-20210130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R13-6-20210130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e31802bf122","article-title":"Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study","volume":"44","author":"Podzamczer","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R14-6-20210130","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"R15-6-20210130","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/QAD.0b013e32832b4377","article-title":"Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment","volume":"23","author":"Haubrich","year":"2009","journal-title":"AIDS"},{"key":"R16-6-20210130","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","article-title":"Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension study","volume":"18","author":"Martin","year":"2004","journal-title":"AIDS"},{"key":"R17-6-20210130","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"},{"key":"R19-6-20210130","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1097\/00002030-200009080-00008","article-title":"Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy","volume":"14","author":"Hatano","year":"2000","journal-title":"AIDS"},{"key":"R22-6-20210130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/aid.2006.22.307","article-title":"Structured intermittent interruption of chronic HIV infection treatment with highly active antiretroviral therapy: effects on leptin and TNF-alpha","volume":"22","author":"Arjona","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R23-6-20210130","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(06)69153-8","article-title":"CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial","volume":"368","author":"Ananworanich","year":"2006","journal-title":"Lancet"},{"key":"R24-6-20210130","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(06)68887-9","article-title":"CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial","volume":"367","author":"Danel","year":"2006","journal-title":"Lancet"},{"key":"R25-6-20210130","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"key":"R26-6-20210130","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/oby.2007.172","article-title":"Visceral and subcutaneous adiposity measurements in adults: influence of measurement site","volume":"15","author":"Ellis","year":"2007","journal-title":"Obesity"},{"key":"R27-6-20210130","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"issue":"Suppl 4","key":"R28-6-20210130","first-page":"A9","article-title":"Greater limb fat increase with intermittent (relative to continuous) thymidine-sparing antiretroviral therapy in HIV-infected patients with lipoatrophy","volume":"13","author":"Martinez","year":"2008","journal-title":"Antivir Ther"},{"key":"R29-6-20210130","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"R30-6-20210130","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/ajcn\/69.6.1162","article-title":"Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging","volume":"69","author":"Engelson","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"R31-6-20210130","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/500398","article-title":"Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort","volume":"42","author":"Manqili","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R32-6-20210130","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/COH.0b013e3282fb7bb9","article-title":"Effectiveness of lipid-lowering therapy in HIV patients","volume":"3","author":"Martinez","year":"2008","journal-title":"Curr Opin HIV AIDS"},{"key":"R33-6-20210130","doi-asserted-by":"crossref","first-page":"15161","DOI":"10.1073\/pnas.261568398","article-title":"Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters","volume":"26","author":"Dybul","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R34-6-20210130","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/0002-8703(85)90224-8","article-title":"Lipids, diabetes, and coronary heart disease: insights from the Framingham study","volume":"110","author":"Kannel","year":"1985","journal-title":"Am Heart J"},{"key":"R35-6-20210130","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV infection and HAART on serum lipids in men","volume":"289","author":"Riddler","year":"2003","journal-title":"JAMA"},{"key":"R36-6-20210130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/135965350801300215","article-title":"Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial","volume":"13","author":"Phillips","year":"2008","journal-title":"Antivir Ther"},{"key":"R37-6-20210130","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1371\/journal.pmed.0050203","article-title":"Inflammatory and coagulation biomarkers and mortality in patients with HIV infection","volume":"5","author":"Kuller","year":"2008","journal-title":"PLoS Med"},{"key":"R38-6-20210130","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e32832995fa","article-title":"HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial","volume":"23","author":"Calmy","year":"2009","journal-title":"AIDS"},{"key":"R39-6-20210130","doi-asserted-by":"crossref","first-page":"e2021","DOI":"10.1371\/journal.pone.0002021","article-title":"Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk","volume":"3","author":"Tebas","year":"2008","journal-title":"PLoS ONE"},{"key":"R40-6-20210130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2337\/diaclin.22.3.141","article-title":"Case study: pitfalls of using hemoglobin A1c as the sole measure of glycemic control","volume":"22","author":"Tran","year":"2004","journal-title":"Clin Diabetes"},{"key":"R42-6-20210130","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1089\/aid.2006.22.1242","article-title":"Inappropriately low glycated hemoglobin values and hemolysis in HIV-infected patients","volume":"12","author":"Diop","year":"2006","journal-title":"AIDS Res Hum Retrovir"},{"key":"R43-6-20210130","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2337\/dc09-0177","article-title":"Hemoglobin A1c underestimates glycemia in HIV infection","volume":"32","author":"Kim","year":"2009","journal-title":"Diabetes Care"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAD.0b013e3283333666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:11:48Z","timestamp":1786039908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-201001280-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,28]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e3283333666","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1,28]]}}}